Literature DB >> 27452478

Analysis of iodinated contrast delivered during thermal ablation: is material trapped in the ablation zone?

Po-Hung Wu1, Chris L Brace.   

Abstract

Intra-procedural contrast-enhanced CT (CECT) has been proposed to evaluate treatment efficacy of thermal ablation. We hypothesized that contrast material delivered concurrently with thermal ablation may become trapped in the ablation zone, and set out to determine whether such an effect would impact ablation visualization. CECT images were acquired during microwave ablation in normal porcine liver with: (A) normal blood perfusion and no iodinated contrast, (B) normal perfusion and iodinated contrast infusion or (C) no blood perfusion and residual iodinated contrast. Changes in CT attenuation were analyzed from before, during and after ablation to evaluate whether contrast was trapped inside of the ablation zone. Visualization was compared between groups using post-ablation contrast-to-noise ratio (CNR). Attenuation gradients were calculated at the ablation boundary and background to quantitate ablation conspicuity. In Group A, attenuation decreased during ablation due to thermal expansion of tissue water and water vaporization. The ablation zone was difficult to visualize (CNR  =  1.57  ±  0.73, boundary gradient  =  0.7  ±  0.4 HU mm(-1)), leading to ablation diameter underestimation compared to gross pathology. Group B ablations saw attenuation increase, suggesting that iodine was trapped inside the ablation zone. However, because the normally perfused liver increased even more, Group B ablations were more visible than Group A (CNR  =  2.04  ±  0.84, boundary gradient  =  6.3  ±  1.1 HU mm(-1)) and allowed accurate estimation of the ablation zone dimensions compared to gross pathology. Substantial water vaporization led to substantial attenuation changes in Group C, though the ablation zone boundary was not highly visible (boundary gradient  =  3.9  ±  1.1 HU mm(-1)). Our results demonstrate that despite iodinated contrast being trapped in the ablation zone, ablation visibility was highest when contrast is delivered intra-procedurally. Therefore, CECT may be feasible for real-time thermal ablation monitoring.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27452478      PMCID: PMC5361223          DOI: 10.1088/0031-9155/61/16/6041

Source DB:  PubMed          Journal:  Phys Med Biol        ISSN: 0031-9155            Impact factor:   3.609


  31 in total

1.  Comparison of the effects of in-vivo thermal ablation of pig liver by microwave and radiofrequency coagulation.

Authors:  T Shibata; T Niinobu; N Ogata
Journal:  J Hepatobiliary Pancreat Surg       Date:  2000

2.  Sonographically observed echogenic response during intraoperative radiofrequency ablation of cirrhotic livers: pathologic correlation.

Authors:  John R Leyendecker; Gerald D Dodd; Glenn A Halff; Victor A McCoy; Dacia H Napier; Linda G Hubbard; Kedar N Chintapalli; Shailendra Chopra; W Kenneth Washburn; Robert M Esterl; Francisco G Cigarroa; Ruth E Kohlmeier; Francis E Sharkey
Journal:  AJR Am J Roentgenol       Date:  2002-05       Impact factor: 3.959

3.  Ultrasound monitoring of temperature change during radiofrequency ablation: preliminary in-vivo results.

Authors:  T Varghese; J A Zagzebski; Q Chen; U Techavipoo; G Frank; C Johnson; A Wright; F T Lee
Journal:  Ultrasound Med Biol       Date:  2002-03       Impact factor: 2.998

Review 4.  Radiofrequency tumor ablation: principles and techniques.

Authors:  S N Goldberg
Journal:  Eur J Ultrasound       Date:  2001-06

5.  New vessel analysis tool for morphometric quantification and visualization of vessels in CT and MR imaging data sets.

Authors:  Tobias Boskamp; Daniel Rinck; Florian Link; Bernd Kümmerlen; Georg Stamm; Peter Mildenberger
Journal:  Radiographics       Date:  2004 Jan-Feb       Impact factor: 5.333

6.  High-intensity focused ultrasound for the treatment of liver tumours.

Authors:  J E Kennedy; F Wu; G R ter Haar; F V Gleeson; R R Phillips; M R Middleton; D Cranston
Journal:  Ultrasonics       Date:  2004-04       Impact factor: 2.890

7.  Monitoring RF ablation.

Authors:  Luigi Solbiati; Massimo Tonolini; Luca Cova
Journal:  Eur Radiol       Date:  2004-10       Impact factor: 5.315

8.  Tumor recurrence after radiofrequency thermal ablation of hepatic tumors: spectrum of findings on dual-phase contrast-enhanced CT.

Authors:  S Chopra; G D Dodd; K N Chintapalli; J R Leyendecker; O I Karahan; H Rhim
Journal:  AJR Am J Roentgenol       Date:  2001-08       Impact factor: 3.959

9.  Computed tomography appearances of hypervascular hepatic tumors after percutaneous radiofrequency ablation therapy.

Authors:  Hanh Vu Nghiem; Isaac R Francis; Robert Fontana; Hero Hussain; Joel F Platt; Ellen Higgins; Robert L Bree
Journal:  Curr Probl Diagn Radiol       Date:  2002 May-Jun

10.  Thermal modeling of lesion growth with radiofrequency ablation devices.

Authors:  Isaac A Chang; Uyen D Nguyen
Journal:  Biomed Eng Online       Date:  2004-08-06       Impact factor: 2.819

View more
  4 in total

1.  Radiofrequency and microwave ablation in a porcine liver model: non-contrast CT and ultrasound radiologic-pathologic correlation.

Authors:  Timothy J Ziemlewicz; J Louis Hinshaw; Meghan G Lubner; Emily A Knott; Bridgett J Willey; Fred T Lee; Christopher L Brace
Journal:  Int J Hyperthermia       Date:  2020       Impact factor: 3.914

2.  Ablation zone visualization enhancement by periodic contrast-enhancement computed tomography during microwave ablation.

Authors:  Po-Hung Wu; Zachary Borden; Christopher L Brace
Journal:  Med Phys       Date:  2017-05-18       Impact factor: 4.071

3.  Feature-based automated segmentation of ablation zones by fuzzy c-mean clustering during low-dose computed tomography.

Authors:  Po-Hung Wu; Mariajose Bedoya; Jim White; Christopher L Brace
Journal:  Med Phys       Date:  2020-12-18       Impact factor: 4.071

Review 4.  Liver microwave ablation: a systematic review of various FDA-approved systems.

Authors:  Simeon J S Ruiter; Wouter J Heerink; Koert P de Jong
Journal:  Eur Radiol       Date:  2018-11-30       Impact factor: 5.315

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.